-
公开(公告)号：US20190388896A1
公开(公告)日：2019-12-26
申请号：US16481409
申请日：2018-01-26
Inventor： Akihiko Taguchi , Yukiko Niino , Takashi Tsumura , Kenichi Morita
Abstract: The mononuclear cell separation apparatus of the present invention has an injecting means (210) for injecting a centrifugation medium from the bottom surface of a container (100) storing a blood sample; a centrifugation means (300) for centrifuging a container (100) containing a centrifugation medium and a blood sample layered in this order from the bottom surface side; a detecting means (400) for detecting a clot present at a mononuclear cell layer after centrifugation; a removing means (220) for removing a detected clot; and a harvesting means (230) for harvesting the mononuclear cell. The mononuclear cell separation method of the present invention includes an injecting step, a centrifuging step, a detection step, a removing step, and a harvesting step corresponding to each constituent element of the mononuclear cell separation apparatus of the present invention.
-
公开(公告)号：US10441611B2
公开(公告)日：2019-10-15
申请号：US14912662
申请日：2014-08-18
Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE , HYOGO COLLEGE OF MEDICINE , NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY , KANEKA CORPORATION
Inventor： Kenichi Yamahara , Akihiko Taguchi , Toshihiro Soma , Shunsuke Ohnishi , Akira Kobayashi
Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
-
公开(公告)号：US10398738B2
公开(公告)日：2019-09-03
申请号：US14912662
申请日：2014-08-18
Applicant: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE , HYOGO COLLEGE OF MEDICINE , NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY , KANEKA CORPORATION
Inventor： Kenichi Yamahara , Akihiko Taguchi , Toshihiro Soma , Shunsuke Ohnishi , Akira Kobayashi
Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.
-
公开(公告)号：US10072242B2
公开(公告)日：2018-09-11
申请号：US14780324
申请日：2014-03-25
Inventor： Hoshimi Kanemura , Masahiro Go , Shin Kawamata , Naoki Nishishita
IPC: C12N5/00 , C12N5/074 , A61K35/545
CPC classification number: C12N5/0081 , A61K35/545 , C12N5/0696
Abstract: The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.
-
15.发明授权公开(公告)号：US11951231B2
公开(公告)日：2024-04-09
申请号：US16966226
申请日：2019-01-31
Applicant: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY , KINKI UNIVERSITY , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Inventor： Takashi Yurube , Yoshiki Takeoka , Koichi Morimoto , Saori Kunii , Kaoru Omae
IPC: A61L27/24 , A61K38/39 , A61L27/50 , A61L27/52 , A61L27/54 , A61P19/08 , A61P43/00 , C07K1/12 , C07K14/78 , C12M1/00 , C12N5/00 , C12N5/077
CPC classification number: A61L27/24 , A61L27/50 , A61L27/52 , C07K14/78 , C12N5/0655
Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.
-
Patent Agency Ranking
公开(公告)号：US20230197213A1
公开(公告)日：2023-06-22
申请号：US16486080
申请日：2018-02-15
Inventor： Keisuke Yuasa , Masahiro Shioya , Tomofumi Nakagawa , Kiyoteru Takenouchi
Abstract: Provided is a medical information management system including: a standardized storage that stores, in a single format, a plurality of pieces of electronic patient record information that is stored in a plurality of electronic patient record servers storing the plurality of pieces of electronic patient record information in different formats; a definition information generator that generates definition information that defines a combination of search keys for retrieving a piece of electronic patient record information on a specific case from among the plurality of pieces of electronic patient record information; a potential case retriever that acquires, based on the definition information, a piece of electronic patient record information on the specific case; and a test value information extractor that extracts test value information, which is clinical information of a patient associated with the specific case from the piece of electronic patient record information acquired by the potential case retriever.
-
公开(公告)号：US11479754B2
公开(公告)日：2022-10-25
申请号：US16095173
申请日：2017-04-19
Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , Foundation for Biomedical Research and Innovation at Kobe
Inventor： Takahiro Nakamura , Shigeru Kinoshita , Seiichi Yokoo , Satoru Yamagami
Abstract: A method for producing an epithelial cell sheet, comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) a ROCK inhibitor.
-
公开(公告)号：US20220011297A1
公开(公告)日：2022-01-13
申请号：US17282637
申请日：2019-10-01
Inventor： Yoshimasa TANAKA , Hiroaki SENJU , Hiroshi MUKAE , Masanori FUKUSHIMA
IPC: G01N33/50 , C12N5/0783
Abstract: A method may predict risk of onset of severe interstitial pneumonia caused by an immune checkpoint inhibitor to achieve a safe and highly effective cancer immunotherapy. Any one or more selected from: (a) cell count or proportion of Vδ2+γδ T cells in peripheral blood mononuclear cells isolated from a subject; (b) cell count or proportion of Vδ2+γδ T cells after antigenic stimulation in peripheral blood mononuclear cells isolated from a subject; (c) cell count or proportion of Vδ2+γδ T cells in peripheral blood T cells isolated from a subject; and (d) cell count or proportion of Vδ2+γδ T cells after antigenic stimulation in peripheral blood T cells isolated from a subject are measured, and the risk of onset of severe interstitial pneumonia is predicted by using the cell count or proportion as an index.
-
公开(公告)号：US20190142820A1
公开(公告)日：2019-05-16
申请号：US16302097
申请日：2017-05-01
Applicant: Tadamasa MATSUMOTO , NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER , FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE
Inventor： Tadamasa MATSUMOTO , Masafumi IHARA , Satoshi SAITO , Masanori FUKUSHIMA
IPC: A61K31/4709 , A61P25/28 , A61K31/353
Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.
-
公开(公告)号：US20240317859A1
公开(公告)日：2024-09-26
申请号：US18290006
申请日：2022-05-12
Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE , NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION , MEIJI SEIKA PHARMA CO., LTD.
Inventor： Tasuku HONJO , Akio OHTA , Masaki TAJIMA , Haruhiko KAMADA , Satoshi NAGATA , Kensuke SUZUKI , Takayoshi FUKUSHIMA , Yosuke TOKUMARU
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/52
Abstract: Conditions necessary for antibodies to human PD-1 to have agonist activity are searched and an optimized agonist antibody is provided based on the conditions and used as a therapeutic for human inflammatory diseases. An agonist antibody to human PD-1 or a functional fragment thereof, wherein the antibody or a functional fragment thereof binds to domain #7 of human PD-1 as shown in SEQ ID NO: 9 is provided.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.021 seconds)
